Do you need two HbA1c tests to diagnose type 2 diabetes? In most cases, yes — UK guidance from NICE (NG28) and the WHO recommends two separate HbA1c results of 48 mmol/mol (6.5%) or above to confirm a diagnosis in people without symptoms. However, a single result may suffice when classic symptoms of hyperglycaemia are present. Understanding when one or two tests are required, which factors can affect HbA1c accuracy, and what happens after diagnosis helps patients and clinicians navigate this important process with confidence.

How HbA1c Is Used to Diagnose Type 2 Diabetes in the UK

HbA1c ≥48 mmol/mol on a venous laboratory sample confirms type 2 diabetes in eligible adults, reflecting average blood glucose over two to three months. It is not appropriate for diagnosis in children, pregnant women, or those with conditions affecting red blood cell turnover.

Have any more questions about this? Message our pharmaceutical team to get more info →

HbA1c (glycated haemoglobin) is the preferred first-line diagnostic test for type 2 diabetes in most adults in the UK. It measures the proportion of haemoglobin in the blood that has glucose attached to it, reflecting average blood glucose levels over the preceding two to three months. Because it provides a longer-term picture of glycaemic control rather than a single point-in-time reading, it is the preferred first-line diagnostic test for most adults — though it is not universally superior to fasting plasma glucose in every clinical situation.

In the UK, a diagnosis of type 2 diabetes is made when the HbA1c level is 48 mmol/mol (6.5%) or above. This threshold was established by the World Health Organisation (WHO) in 2011 and is endorsed by both NICE (NG28) and NHS England. The test does not require the patient to fast beforehand, making it a practical and accessible diagnostic tool in primary care.

Importantly, for a diagnosis to be valid, HbA1c must be measured using a venous blood sample analysed in an accredited laboratory using an IFCC-aligned, quality-assured assay. Point-of-care HbA1c devices (such as those used in some GP surgeries for monitoring) are not suitable for diagnostic purposes.

HbA1c is not appropriate for diagnosis in all situations. NICE NG28 specifies that HbA1c should not be used to diagnose diabetes in the following groups:

• Children and young people

• People with symptoms of diabetes lasting fewer than two months

• People who are acutely unwell (e.g., during intercurrent illness or hospital admission)

• People in whom type 1 diabetes is suspected

• Pregnant women

• People with conditions that affect red blood cell turnover or haemoglobin structure (see the section on factors affecting HbA1c accuracy)

In these circumstances, a plasma glucose measurement — fasting (≥7.0 mmol/L) or random (≥11.1 mmol/L with symptoms) — or a 75 g oral glucose tolerance test (OGTT) should be used instead. The number of tests required before a formal diagnosis can be confirmed depends on whether the patient has symptoms and how clearly abnormal the result is.

When Two HbA1c Tests Are Required for Diagnosis

Two separate HbA1c results of ≥48 mmol/mol are required to diagnose type 2 diabetes in asymptomatic individuals, in line with WHO 2011 and NICE NG28 guidance. If results are discordant, a fasting plasma glucose or OGTT should be used to resolve uncertainty.

In most cases where a person does not have clear symptoms of diabetes, two separate HbA1c measurements are required to confirm a diagnosis of type 2 diabetes. This approach reduces the risk of a false-positive diagnosis resulting from a transient elevation or analytical error, and is consistent with WHO 2011 and NICE NG28 guidance.

The two tests should ideally be:

• Taken on two separate occasions

• Both returning a result of 48 mmol/mol (6.5%) or above

• Performed in the absence of acute illness, which can temporarily elevate blood glucose

• Analysed using the same method and laboratory where feasible, to minimise analytical variation between samples

This two-test requirement applies to the majority of people identified through routine screening — for example, during an NHS Health Check, or when blood tests are taken for an unrelated condition. In these situations, the person may feel entirely well and have no classic symptoms such as increased thirst, frequent urination, or unexplained weight loss.

If the two HbA1c results are discordant (for example, one is above 48 mmol/mol and the other is not), clinicians should not rely on a third HbA1c alone. In this situation, a fasting plasma glucose or OGTT may be used to resolve the uncertainty, and clinical care should not be unnecessarily delayed. A result between 42–47 mmol/mol indicates non-diabetic hyperglycaemia (sometimes called prediabetes), which warrants lifestyle intervention and annual monitoring rather than an immediate diabetes diagnosis.

When a Single HbA1c Result May Be Sufficient

A single HbA1c ≥48 mmol/mol is sufficient for diagnosis when classic hyperglycaemic symptoms — such as polydipsia, polyuria, or unexplained weight loss — are present. HbA1c should not be used alone if type 1 diabetes is suspected or symptoms have lasted fewer than two months.

There are specific clinical circumstances in which a single HbA1c result is sufficient to confirm a diagnosis of type 2 diabetes, without the need for a second confirmatory test. This applies when a person presents with unequivocal symptoms of hyperglycaemia — such as polydipsia (excessive thirst), polyuria (frequent urination), unexplained weight loss, or blurred vision — alongside an HbA1c of 48 mmol/mol or above.

In these cases, the combination of classic symptoms and a clearly elevated HbA1c provides sufficient diagnostic certainty. Delaying diagnosis to await a second test in a symptomatic individual could result in unnecessary harm.

Important exceptions: Even in the presence of symptoms, HbA1c should not be used as the sole diagnostic test if:

• Type 1 diabetes is suspected (particularly in younger people or those with rapid symptom onset, significant weight loss, or ketonuria)

• Symptoms have been present for fewer than two months

• The person is acutely unwell, pregnant, or has a condition affecting HbA1c reliability

In these situations, a random plasma glucose ≥11.1 mmol/L (with symptoms) or fasting plasma glucose ≥7.0 mmol/L should be used for diagnosis.

Red-flag symptoms requiring urgent same-day assessment include severe thirst with vomiting, abdominal pain, rapid breathing, drowsiness or confusion, or a smell of ketones on the breath. These may indicate diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS) and require immediate emergency medical attention — patients should call 999 or go to A&E without delay. Patients should always report any new or worsening symptoms promptly to their GP rather than waiting for routine follow-up.

Factors That Can Affect HbA1c Accuracy and Reliability

Several conditions can cause falsely low or high HbA1c results, including haemolytic anaemia, iron deficiency, haemoglobinopathies, and advanced chronic kidney disease. In these cases, fasting plasma glucose or a 75 g OGTT should be used for diagnosis instead.

While HbA1c is a robust and widely validated diagnostic test, several conditions and circumstances can affect its accuracy, potentially leading to falsely high or falsely low results. Clinicians must be aware of these limitations, particularly when results appear inconsistent with a patient's clinical presentation. Where HbA1c reliability is in doubt, fasting plasma glucose or a 75 g OGTT should be used instead, as recommended by NICE NG28.

Conditions that may cause falsely LOW HbA1c:

• Haemolytic anaemia (increased red blood cell turnover reduces HbA1c exposure time)

• Recent blood transfusion

• Advanced chronic kidney disease (stages 4–5 and dialysis) — reduced red cell lifespan typically lowers HbA1c, making it unreliable in this group

• Some haemoglobin variants (effects are assay-dependent; see below)

• Pregnancy (altered red cell lifespan)

Conditions that may cause falsely HIGH HbA1c:

• Iron deficiency anaemia — this typically raises HbA1c, and values generally fall following iron replacement therapy

• Vitamin B12 or folate deficiency

• Splenectomy

Haemoglobin variants (e.g., sickle cell trait, haemoglobin C, D, or E): The direction of interference — whether HbA1c is falsely raised or lowered — depends on the specific variant and the assay method used. Clinicians should consult their local laboratory for guidance on which assays are affected. In patients with known haemoglobinopathies, plasma glucose or OGTT is preferred for diagnosis.

Patients should also be aware that certain medications — including high-dose corticosteroids and some antipsychotics — can raise blood glucose levels and may influence HbA1c readings over time. If there is any concern about the reliability of a result, patients should discuss this with their GP or practice nurse.

For diagnostic purposes, only an IFCC-aligned, quality-controlled laboratory assay should be used. Local laboratory guidance (e.g., from RCPath or UK NEQAS) should be consulted when assay interference is suspected.

What Happens After a Confirmed Type 2 Diabetes Diagnosis

After diagnosis, patients undergo structured review covering cardiovascular risk, kidney function, eye and foot health, and are referred to a structured education programme such as DESMOND. Metformin is the standard first-line medication per NICE NG28, with SGLT2 inhibitors recommended for those with high cardiovascular or renal risk.

Once a diagnosis of type 2 diabetes has been confirmed, the focus shifts to structured assessment, education, and the initiation of an individualised management plan. In the UK, this process is largely coordinated through primary care, with referral to specialist services when required.

Following diagnosis, patients can typically expect:

• A structured diabetes review including assessment of cardiovascular risk, kidney function (eGFR and urine albumin-to-creatinine ratio), eye health (NHS diabetic eye screening), and foot health

• Referral to a structured education programme, such as the NHS-commissioned Diabetes Education and Self Management for Ongoing and Newly Diagnosed (DESMOND) programme

• Lifestyle advice covering diet, physical activity, weight management, and smoking cessation

• Initiation of medication if lifestyle measures alone are insufficient

Per NICE NG28, metformin remains the standard first-line pharmacological treatment for most people with type 2 diabetes. It works by reducing hepatic glucose production and improving insulin sensitivity. It is generally well tolerated, though gastrointestinal side effects (nausea, diarrhoea) are common initially and can be minimised by taking it with food or using a modified-release formulation. Metformin should be used with caution in renal impairment: the dose should be reviewed when eGFR falls below 45 mL/min/1.73 m², and it should be avoided if eGFR is below 30 mL/min/1.73 m². Patients should also be advised about sick-day rules (temporarily stopping metformin during acute illness or dehydration).

For people with established cardiovascular disease, high atherosclerotic cardiovascular risk, or chronic kidney disease, NICE NG28 recommends considering an SGLT2 inhibitor (such as empagliflozin, dapagliflozin, or canagliflozin) as part of first-line treatment, with or without metformin, given their evidence-based cardiovascular and renal protective benefits. GLP-1 receptor agonists may also be considered where significant weight loss or cardiovascular benefit is a priority. Patients should discuss the most appropriate treatment option with their GP or diabetes care team.

If you experience any suspected side effects from diabetes medicines, you can report these to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Ongoing monitoring includes HbA1c testing every three to six months until targets are stable, then every six months thereafter (NICE NG28). Patients should be encouraged to engage actively with their care team and report any new symptoms — including signs of hypoglycaemia if additional medications are introduced — to their GP promptly.

Current NICE and NHS Guidance on Diabetes Diagnostic Testing

NICE NG28 and WHO 2011 guidance require two HbA1c results ≥48 mmol/mol for diagnosis in asymptomatic individuals, or one result with classic symptoms. HbA1c 42–47 mmol/mol indicates non-diabetic hyperglycaemia, warranting referral to the NHS Diabetes Prevention Programme.

The primary UK guidance on the diagnosis and management of type 2 diabetes is set out in NICE guideline NG28 (Type 2 diabetes in adults: management). Prevention of type 2 diabetes in people at high risk is addressed in NICE guideline PH38 (Type 2 diabetes: prevention in people at high risk). These documents are regularly updated to reflect evolving evidence and should be the reference point for both clinicians and informed patients. The diagnostic threshold of 48 mmol/mol is underpinned by the WHO 2011 report on the use of HbA1c in the diagnosis of diabetes mellitus.

Key diagnostic principles from current NICE and NHS guidance include:

• HbA1c ≥48 mmol/mol on two separate occasions (in asymptomatic individuals) confirms type 2 diabetes

• A single HbA1c ≥48 mmol/mol is sufficient in the presence of classic hyperglycaemic symptoms, provided HbA1c is appropriate to use in that individual

• HbA1c 42–47 mmol/mol indicates non-diabetic hyperglycaemia and warrants lifestyle intervention and annual monitoring

• Alternative diagnostic tests (fasting plasma glucose or OGTT) should be used when HbA1c is unreliable or contraindicated

• Diagnosis must be made using a venous sample in an accredited laboratory; point-of-care HbA1c is not suitable for diagnosis

The NHS Diabetes Prevention Programme (NHS DPP) plays an important role in identifying and supporting individuals with non-diabetic hyperglycaemia before they progress to a formal diagnosis. Referral to this programme is recommended for eligible patients identified in primary care, in line with NICE PH38.

Patients who are uncertain about their test results, concerned about symptoms, or who have a strong family history of diabetes are encouraged to speak with their GP. Early diagnosis and proactive management significantly reduce the risk of long-term complications, including cardiovascular disease, diabetic retinopathy, nephropathy, and neuropathy. Staying engaged with regular reviews and NHS-recommended monitoring remains the cornerstone of effective diabetes care in the UK.

Key references: NICE NG28 (Type 2 diabetes in adults: management); NICE PH38 (Type 2 diabetes: prevention in people at high risk); WHO 2011 (Use of HbA1c in the diagnosis of diabetes mellitus); NHS website: Diabetes — diagnosis; NHS Diabetes Prevention Programme; BNF/MHRA SmPC for metformin.

Frequently Asked Questions